This page is about why equal milligrams across GLP-1 compounds do not mean equal doses, and why that gap matters most when you try to stack two of them. It is written for the researcher comparing semaglutide, tirzepatide, and retatrutide, or running two together, who wants to understand what the milligram figure is hiding. The short version is that the dose that matters is the one each receptor sees, and that split is something the drug companies have not published for any of these compounds.

Why a milligram is not a dose

Here is the thing almost nobody accounts for with these compounds. The same number of milligrams does not mean the same dose. That number only tells you the same weight of powder sits in the vial. What actually matters is which receptor that powder is hitting and how hard.

A receptor is just a docking point on your cells, meaning a spot where a compound plugs in and sends a signal. Semaglutide, tirzepatide, and retatrutide do not plug into the same set of docking points, and even where they share one, they do not press on it with the same force. So two vials can read three milligrams each and deliver completely different instructions to your body. The milligram is a measure of mass. The dose is a measure of signal, and signal is what drives the result.

This is why comparing these compounds by milligram is a category error. You are comparing the weight of two envelopes without knowing what either letter says.

If the question in your head right now is whether your current milligram is actually a low dose or a high one for the compound you are running, ask it here and the first answer shows in full for free.

Semaglutide works on one receptor

Start with the oldest of the three, semaglutide. It works on one signal, the GLP-1 receptor. GLP-1 is a gut hormone, meaning a signal your intestine releases, and it does two main things. It lowers appetite and it helps control blood sugar.

Now picture three milligrams of semaglutide. Almost all of that three milligrams is aimed at that one GLP-1 signal. That is the whole payload going to a single docking point. Hitting one receptor that hard has a cost. It is part of why semaglutide tends to be harder to tolerate for a lot of people. More of the appetite signal concentrated in one place usually means more nausea, because the compound has only one lever to pull and it pulls it all the way.

That is the baseline to hold onto. A single-receptor compound puts its entire weight on one pathway, and the side effect profile reflects that.

Tirzepatide adds a second receptor

Tirzepatide works on two signals, not one. It keeps the GLP-1 appetite signal from semaglutide and adds a second one called GIP. GIP is another gut hormone, meaning a second signal from your digestive system, and it changes how the whole thing behaves.

What you cannot see on the label

Now picture three milligrams of tirzepatide. Here is what the vial does not tell you. You do not know how much of that three milligrams is working the GLP-1 receptor and how much is working the GIP receptor. The companies behind these drugs do not publish that split. So when someone says they are running three milligrams, the milligram is real but the dose at each receptor is a black box, even to them.

Why the second receptor is doing more than softening side effects

This is the part people miss. Adding GIP did more than take the edge off the nausea. Adding GIP also meant less GLP-1 signaling was needed to get the same weight loss. The appetite signal is doing less of the work in tirzepatide than it does in semaglutide. That is the real reason tirzepatide is usually easier on users than semaglutide is. It is not that tirzepatide is gentler by accident. It is that the load got spread across two receptors instead of being dumped on one.

Retatrutide adds a third

Retatrutide works on three signals, not two. It keeps GLP-1 and GIP from tirzepatide and adds a third one called glucagon. Glucagon is a signal that tells your body to burn stored energy, not just to eat less. That is a different kind of instruction. The first two receptors mostly manage intake, meaning how much you take in. Glucagon works on output, meaning what your body does with the energy it already has stored.

Now picture those same three milligrams, but this time it is three milligrams of retatrutide. You are even further in the dark than you were with tirzepatide. No one outside the drug company knows how heavy retatrutide is on the GLP-1 receptor. No one knows how heavy it is on GIP. And no one knows how heavy it is on glucagon. That three-way split is simply not public data. You have three docking points and no published numbers for any of them.

The same trend still holds, though. Retatrutide leans on the appetite signal less than tirzepatide does, and that is a big reason retatrutide is often more tolerable than tirzepatide despite being the more powerful compound on paper. The more receptors there are to share the work, the less any single one has to carry.

Each generation leans on appetite less

Put the three side by side and a clear pattern shows up. Each generation of these GLP-1 compounds leans on the appetite signal less than the one before it, because each one has added another receptor to spread the load across. Semaglutide has one lever. Tirzepatide has two. Retatrutide has three.

Less weight on the appetite signal tends to mean less of the nausea, the food aversion, and the gut distress that come with these compounds. This is why the newest compound can be the strongest for fat loss and, for many people, the easiest to sit with at the same time. That combination sounds contradictory until you understand it is about distribution, not just power.

Read that table as a direction, not as a dosing chart. It describes which receptors each compound engages, based on how these drugs were designed and studied. It does not tell you the exact strength at each receptor, because that is the number no one has published.

What happens when you stack two of them

This is where the milligram problem stops being academic and starts costing you clarity. Take the setup that sparked this whole breakdown, a researcher running both tirzepatide and retatrutide in the same week. Spacing the two doses across the week is a smart instinct, because it gives each compound room before the next one lands. But there is an honest limit to what spacing can do.

Both tirzepatide and retatrutide hit the GLP-1 receptor. They share that one appetite signal. So when you run both, you get overlap on the shared receptor, and you cannot map that overlap cleanly. Remember, no one has the receptor split for either compound. So you cannot know how much GLP-1 signal you are adding on top of GLP-1 signal. You can space the doses to make the overlap smaller. You cannot remove it, and the numbers you would need to remove it do not exist.

The researcher stacking two of these compounds is the one most exposed to a signal he cannot measure, because he is doubling up on the one receptor all three generations share while flying blind on the split. That is not a reason the stack cannot work. It is a reason you cannot claim precision you do not have.

The part worth copying

Step back from the compounds for a second, because you may never run two of these together. Either way, the way this particular result was tracked is the part worth studying. Body composition was checked with a clinical scan that measures fat and muscle separately, not just a number on a bathroom scale. Blood pressure and resting heart rate were tracked too. Those are basic safety markers that most people stacking these compounds never check, and they are the difference between knowing your result and assuming it.

The reported figures in that setup were a loss of 43 pounds of body fat and a gain of 3 pounds of muscle, with blood pressure around 117 over 75 and a resting heart rate in the low 70s. Treat those as what was reported by one researcher through his clinic, not as a target or a promise. The point is not the numbers. The point is that they were measured against a baseline instead of eyeballed.

There is one more thing that researcher did right. He named the testosterone in his setup instead of leaving it out. Naming what else is in play, rather than crediting the headline compound for everything, is exactly what honest research looks like, and it is where most posts about these stacks fall apart.

Why testosterone changes how you read the muscle result

Losing fat and gaining muscle at the same time is called recomposition, meaning your body composition improves in both directions at once. Recomposition is hard to do on its own, and it is especially hard while running aggressive fat-loss compounds that can cost you lean muscle along the way. So when a GLP-1 stack result shows muscle gain alongside heavy fat loss, the first question a careful researcher asks is what else was in the setup.

What testosterone is actually doing here

Here is why testosterone matters so much. Testosterone replacement, meaning an exogenous source you are adding rather than what your body makes on its own, protects muscle tissue. Stacking two fat-loss compounds pushes the muscle-loss risk harder, not softer. So the muscle in a result like this is very likely not the two GLP-1 compounds doing the work. It is more likely the testosterone holding onto muscle while the compounds strip fat. Take the testosterone out of that same setup and the muscle side of the result can look completely different.

This is the detail that separates reading a stack correctly from drawing the wrong lesson from it. The best research credits the right tool for the right job. Here, the GLP-1 compounds are doing the fat loss and the testosterone is doing the muscle protection. Crediting the GLP-1 stack for the muscle gain is how a researcher ends up chasing a result the compounds alone were never going to give him. If you are on TRT and running a GLP-1, our breakdown of whether retatrutide lowers testosterone covers the other half of that interaction.

How to read any stack result like this

When you see a before-and-after from a GLP-1 stack, run it through three questions before you copy it. What was actually measured, which compound owns which part of the result, and what else was in the setup that is not in the headline. Most posts answer none of these, which is why most posts are useless for making a decision.

What this does and does not settle

None of this is a verdict on whether running tirzepatide and retatrutide together is a good idea or a bad one. That is not the call this page is making. Can you run both and see a real result? The tracked numbers in that researcher's setup say you can. Can you run both and know exactly what you are doing at each receptor? Based on the published data, no, you cannot, because the receptor split for either compound is not available.

That gap is not a knock on any researcher attempting the stack. It is a knock on the data, which is not there yet. What you can do is exactly what the better results do. Track real markers instead of guessing, use a clinical scan instead of a mirror, and name everything in the setup instead of pretending the headline compound did all the work. If it is working and your markers look clean, that counts. Keep reading your own body and your own bloodwork, not someone else's post. For the wider stacking logic, our guide on stack compatibility walks through which compounds share a pathway and which do not.

Pulling it together

Equal milligrams of these compounds are not equal doses. The milligram measures powder, not signal, and the signal at each receptor is the number no one has published. Stack two of them and you add overlap on the shared GLP-1 receptor that you cannot measure or fully remove. And with any result like the one that started this, you have to read the entire setup, not just one compound, because the testosterone in the mix is very likely doing real work the GLP-1 stack is getting credit for.

Frequently asked

If you still have a question this page did not settle, something like whether 5 mg of retatrutide is stronger than 5 mg of tirzepatide, type it into the Research Engine and the first answer shows in full for free.

For research and educational purposes only. Not medical advice.